CLARITY

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

Retrieved on: 
Wednesday, April 3, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Clinical Trials, CLARITY, Therapy, Presbyopia

Near vision improvement was reproducible and consistent across both CLARITY 1 and 2 throughout the four-week study periods.

Key Points: 
  • Near vision improvement was reproducible and consistent across both CLARITY 1 and 2 throughout the four-week study periods.
  • LNZ100 was well-tolerated with no serious treatment-related adverse events observed in the over 30,000 treatment days across all three CLARITY trials.
  • “We are very pleased with the outcome of the CLARITY trials, and most importantly the strong efficacy and safety profile of LNZ100 observed in patients with presbyopia.
  • It is comprised of two six-week efficacy trials, CLARITY 1 and 2, and a six-month safety trial, CLARITY 3.

Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs

Retrieved on: 
Monday, March 4, 2024
Paper, Comparison, Algorithm, PD, ACON, Gold standard, Physician, Pain, Surgeon, Discography, International Society, Biomarker, Software as a service, CLARITY, Patient, Canadian International Council, Diagnosis, Low back pain, CO, Research, Medical imaging

BROOMFIELD, CO, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the publication of the clinical paper, Establishing a Gold Standard for Noninvasive Identification of Painful Lumbar Discs: Prospective Comparison of Magnetic Resonance Spectroscopy vs Low-Pressure Provocation Discography by the International Journal of Spine Surgery, the official scientific journal of the International Society for the Advancement of Spine Surgery (ISASS).

Key Points: 
  • Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan provides better information to surgeons.
  • Low-pressure provocative discography (PD) has served as the gold standard, despite well-documented drawbacks including being highly invasive and presenting difficult-to-interpret results.
  • Achieving a result of 100% sensitivity (5/5 lumbar discs) means that in this study if discography indicates a disc is painful, then Nociscan will also indicate that the disc is painful.
  • We look forward to introducing Nociscan to a growing number of physicians and patients.”
    Access to the publication can be found here.

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Retrieved on: 
Monday, February 5, 2024
Partnership, CO, Surgeon, FACS, CLARITY, Biomedicine, Biomarker, Patient, ACON, Physician, Biomedical engineering, Algorithm, KOL, Johns Hopkins, Medical device

BROOMFIELD, CO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it has completed several recent financing transactions that have significantly reduced debt and increased available cash. The Company believes these financing transactions will assist in achieving key milestones that include initiating the CLARITY trial, onboarding additional KOL surgeons through the strategic partnership with Alphatec, and continuing to increase Nociscan orders.

Key Points: 
  • The Company believes these financing transactions will assist in achieving key milestones that include initiating the CLARITY trial, onboarding additional KOL surgeons through the strategic partnership with Alphatec, and continuing to increase Nociscan orders.
  • The Company believes these recent financing transactions were on terms more favorable than those available in the public capital markets.
  • The Company expects to add 5 new KOLs to the Nociscan network in the first half of 2024.
  • The Company will provide updates as clinical sites are added to CLARITY and KOLs are onboarded through the strategic partnership.

Neurent Medical Announces New CPT Code® for Chronic Rhinitis Treatment Offering Significant Symptom Improvements

Retrieved on: 
Monday, November 13, 2023
PNN, Sleep, Safety, Prevalence, Congestion, Nose, Medical classification, CPT, Patient, FACS, Inflammation, Sneeze, ENT, CMS, Partnership, CLARITY, Growth, Medicare, Rhinorrhea, Public, Physician, Radiofrequency ablation, Northwest Kidney Centers

GALWAY, Ireland, Nov. 13, 2023 /PRNewswire/ -- Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced a significant milestone for the chronic rhinitis market. The Centers for Medicare and Medicaid Services (CMS) has recently assigned a Category I Current Procedural Terminology (CPT®) reimbursement code for a breakthrough minimally invasive procedure designed to address the symptoms of patients suffering from chronic rhinitis.

Key Points: 
  • GALWAY, Ireland, Nov. 13, 2023 /PRNewswire/ -- Neurent Medical , a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced a significant milestone for the chronic rhinitis market.
  • The establishment of this CPT code is a significant milestone for physicians who treat chronic rhinitis patients.
  • The new code describes the procedure performed by otolaryngologists or ear, nose, and throat (ENT) physicians when disrupting overactive nerves that drive chronic rhinitis symptoms.
  • It is estimated that several million chronic rhinitis patients are seen by ENT doctors annually in the United States.

Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the NIA-sponsored CLARiTI Trial

Retrieved on: 
Monday, November 6, 2023
Research, Neurology, Genetics, Other Health, Biotechnology, Radiology, General Health, Health, Science, Other Science, NIA, Biomarker, Deficit spending, PET, Drug development, Meilleur, Disease, Disorder, Partnership, Lead, Pathology, Patient, CLARITY, Acceleration, Pharmaceutical industry, Medical imaging

The collaboration will involve the network of Alzheimer’s Disease Research Centers across the country (currently, there are 37 centers of excellence), will recruit 2000 subjects, and apply cutting-edge imaging and blood-based biomarkers to investigate the multiple intersecting neurodegenerative causes of cognitive impairment (known collectively as Alzheimer’s disease and related disorders or ADRD).

Key Points: 
  • The collaboration will involve the network of Alzheimer’s Disease Research Centers across the country (currently, there are 37 centers of excellence), will recruit 2000 subjects, and apply cutting-edge imaging and blood-based biomarkers to investigate the multiple intersecting neurodegenerative causes of cognitive impairment (known collectively as Alzheimer’s disease and related disorders or ADRD).
  • Sterling Johnson, the CLARiTI STUDY Lead, stated: “A major gap in our field is the ability to detect and develop a temporal profile of the several pathologies that may be present in our older patients with cognitive symptoms.
  • This requires a broad panel of biomarkers.
  • We applaud the NIA and the ADRC for their initiative.”

Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting

Retrieved on: 
Thursday, October 19, 2023
Week, Alzheimer's disease, Amyloid, Patient, AD, Biogen, Clarity, MAPT, HIV disease progression rates, Clinical trial, BIIB, PET, LTE, Caregiver, CLARITY, Biomarker, Safety, Pharmaceutical industry, Medical imaging

CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer’s disease portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) meeting taking place October 24-27 in Boston, Mass.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer’s disease portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) meeting taking place October 24-27 in Boston, Mass.
  • The presentations will advance the understanding of Alzheimer’s disease with data on different treatment approaches, predictive analysis of disease progression, and clinical meaningfulness of amyloid removal for patients and their caregivers.
  • The presentation will include the latest data from the CLARITY AD optional tau PET longitudinal sub-study.
  • Oral presentation: Precision medicine analysis of heterogeneity in individual-level treatment response to beta-amyloid removal in early Alzheimer’s disease: Thursday, October 26, 4:35 p.m.

Global Investor ESG Software Market Landscape 2023-2030: The Rise of Purpose-Built Software Solutions for Streamlining Data and Driving Investor Demand - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 29, 2023
Technology, Software, Component, Maintenance, COVID-19, Risk management, Data collection, PLAN, Organization, Compound annual growth rate, Refinitiv, Small and medium-sized enterprises, OWN, CLARITY, Biophysical environment, Growth, ESG, SME, Asset management

Greenstone+ Ltd, a notable contender in the investor ESG software market, highlights the growing standardization of ESG factors in investment decisions.

Key Points: 
  • Greenstone+ Ltd, a notable contender in the investor ESG software market, highlights the growing standardization of ESG factors in investment decisions.
  • This trend is compelling investors to seek purpose-built ESG software that facilitates data collection, tracking, and efficient analysis across portfolios, thereby propelling the investor ESG software market.
  • The demand for investor ESG services has surged in response to the need for holistic solutions, contributing to the expansion of the investor ESG software market.
  • The investor ESG software market is segmented based on two key factors:
    Component: The market is divided into software and services.

Nanaimo, B.C., Modernizes Permitting and Approvals Process with Clariti

Retrieved on: 
Tuesday, August 15, 2023
Apps, Applications, Technology, Construction & Property, Urban Planning, Public Policy, Government, Building Systems, Software, State, Local, Other Construction & Property, Engineering, City, Population growth, GIS, Warehouse, Risk management, CLARITY

Implementation of the new platform is underway, led by trusted Clariti partner Avocette Technologies .

Key Points: 
  • Implementation of the new platform is underway, led by trusted Clariti partner Avocette Technologies .
  • Overall, the city’s goals for the project are to:
    Simplify and accelerate the permit application process for customers.
  • Streamline the plan review and approval process to reduce the time between submission, acceptance, and approval, and help the city meet its performance targets.
  • Modernize the inspections process using a mobile application that allows inspectors to take their office into the field.

Clariti and SolarAPP+ Partner to Streamline Residential Solar Permit Issuance

Retrieved on: 
Tuesday, August 1, 2023
Public Policy, Government, Software, Defense, State, Local, Alternative Energy, Energy, Technology, Government Technology, Partnership, Safety, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Renewable energy, CLARITY

Clariti, a provider of community development , permitting, and licensing software for North America’s largest and fastest-growing communities, and SolarAPP+ , an online platform that helps communities streamline the process of obtaining permits for rooftop solar installations, have partnered to streamline the review and inspection process for residential solar permits.

Key Points: 
  • Clariti, a provider of community development , permitting, and licensing software for North America’s largest and fastest-growing communities, and SolarAPP+ , an online platform that helps communities streamline the process of obtaining permits for rooftop solar installations, have partnered to streamline the review and inspection process for residential solar permits.
  • The partnership makes it easier for residents to obtain solar permits, helping to encourage the adoption of renewable energy throughout the United States.
  • This helps reduce the time and cost of obtaining solar permits and makes homeowners’ transition to renewable energy more accessible.
  • SolarAPP+ simplifies the requirements for residential solar permits and ensures safety and compliance by detecting real-time code issues, typos, and errors.

MycoDog Announces Partnership with Two Crazy Cat Ladies

Retrieved on: 
Thursday, July 27, 2023
Blood pressure, Taste, Partnership, Pacific Northwest, Bacopa monnieri, Cancer, Natural, Research, Fungus, Grain, Turkey, Animal, CLARITY, Dog, Nervous system, Immune system, Viral, Liver, Cat, Soft drink, Salt, Medicinal plants, Lingzhi (mushroom), Trametes versicolor, Withania somnifera, Cordyceps

BREATHE tonic—recommended for respiratory and cardiovascular support—contains extract of the fruiting body of Cordyceps, Reishi, Artist Conk and Chaga, with Ashwagandha, Distilled Water and Organic Vegetable Glycerin.

Key Points: 
  • BREATHE tonic—recommended for respiratory and cardiovascular support—contains extract of the fruiting body of Cordyceps, Reishi, Artist Conk and Chaga, with Ashwagandha, Distilled Water and Organic Vegetable Glycerin.
  • MycoCat tonics are preserved in organic vegetable glycerin rather than alcohol, ensuring cats will prefer the taste over alcohol preservatives.
  • In addition, mushroom extract tonics are more bioavailable than powdered versions since they can be absorbed into the bloodstream upon consumption.
  • They are from mushrooms grown, wild-harvested, extracted, and packaged in the USA, and exclusively available at www.twocrazycatladies.com/shop/
    Angela Ardolino and Two Crazy Cat Ladies will be appearing with CBD Dog Health at SuperZoo Pet Retail Event, Booth #3103 (Naturals Section), Mandalay Bay, Las Vegas, August 16-18, 2023.